Botanix Pharmaceuticals Limited
BOT
Rank in Stocks
#28095
Botanix Pharmaceuticals Limited, an Australian enterprise, is dedicated to the... Botanix Pharmaceuticals Limited, an Australian enterprise, is dedicated to the discovery and advancement of novel dermatological and antimicrobial therapeutic agents. The company's central mission involves pioneering innovative treatments for widespread skin conditions and various infections. Its robust developmental portfolio showcases several key assets: Sofpironium Bromide, which has successfully completed Phase 3 clinical studies for managing primary axillary hyperhidrosis; BTX 1503, a transdermal gel designed to tackle severe acne in both adults and teenagers, having concluded Phase II trials; BTX 1801, which has progressed through Phase IIb clinical investigations for infections caused by Staphylococcus aureus (including its methicillin-resistant variant); BTX 1702, currently undergoing Phase IIb clinical evaluation for papulopustular rosacea; and BTX 1204A, targeting atopic dermatitis. Established in 1984, Botanix Pharmaceuticals operates from its headquarters in Leederville, Australia.
Share Price
$0.00622971
Last synced: 2026-11-10
Market Cap
$12.41M
Change (1 day)
-10.00%
Change (1 year)
-92.36%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Botanix Pharmaceuticals Limited (BOT)
Category
Healthcare
EPS for Botanix Pharmaceuticals Limited (BOT)
EPS as of June 2026 TTM: $-0.02
According to Botanix Pharmaceuticals Limited's latest financial reports, its current EPS (TTM) is $-0.02. At the end of 2025 the company had an EPS of $-0.03, a decrease compared to its 2024 EPS of $-0.01.
EPS history for Botanix Pharmaceuticals Limited from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.02 | -24.33% |
| 2025 | $-0.03 | 404.92% |
| 2024 | $-0.01 | 15.09% |
| 2023 | $-0.01 | -43.01% |
| 2022 | $-0.01 | 272.00% |
| 2021 | 0.00 | -79.84% |
| 2020 | $-0.01 | -21.02% |
| 2019 | $-0.02 | -5.99% |
| 2018 | $-0.02 | 96.47% |
| 2017 | $-0.01 | 6.25% |
| 2016 | $-0.01 | -11.11% |
| 2015 | $-0.01 | -65.12% |
| 2014 | $-0.03 | -93.43% |
| 2013 | $-0.39 | 9,254.76% |
| 2012 | 0.00 | 68.00% |
| 2011 | 0.00 | -3.85% |
| 2010 | 0.00 | -99.94% |
| 2009 | $-4.31 | -17.21% |
| 2008 | $-5.21 | -16.08% |
| 2007 | $-6.21 | 24.93% |
| 2006 | $-4.97 | -93.25% |
| 2005 | $-73.65 | 4,332,341.18% |
| 2004 | 0.00 | -32.00% |
| 2003 | 0.00 | 19.05% |
| 2002 | 0.00 | 320.00% |
| 2001 | 0.00 | -80.00% |
| 2000 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -69,086.78% |
US
|
|
| $-7.07 | 31,045.37% |
US
|
|
| $-5.29 | 23,203.96% |
AU
|
|
| $12.88 | -56,840.53% |
BE
|
|
| $21.56 | -95,077.97% |
NL
|
Questions about Botanix Pharmaceuticals Limited's earnings per share (EPS)
What is Botanix Pharmaceuticals Limited's earnings per share (EPS)?
Botanix Pharmaceuticals Limited's earnings per share (EPS) over the last twelve months is $-0.02, as of Jun 2026.
What was Botanix Pharmaceuticals Limited's earnings per share (EPS) in 2025?
In 2025, Botanix Pharmaceuticals Limited's earnings per share (EPS) was $-0.03, compared with $-0.01 in 2024.
How has Botanix Pharmaceuticals Limited's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Botanix Pharmaceuticals Limited's earnings per share (EPS) was highest in 2021 (0.00) and lowest in 2025 ($-0.03).
How does Botanix Pharmaceuticals Limited's earnings per share (EPS) compare with similar companies?
Botanix Pharmaceuticals Limited's earnings per share (EPS) ($-0.02) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.